Literature DB >> 22847520

[Conventional versus hypofractionated intensity-modulated radiotherapy for prostate cancer].

R Pahl1.   

Abstract

Entities:  

Year:  2012        PMID： 22847520     DOI： 10.1007/s00066-012-0167-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  4 in total

1.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial.

Authors:  David Dearnaley; Isabel Syndikus; Georges Sumo; Margaret Bidmead; David Bloomfield; Catharine Clark; Annie Gao; Shama Hassan; Alan Horwich; Robert Huddart; Vincent Khoo; Peter Kirkbride; Helen Mayles; Philip Mayles; Olivia Naismith; Chris Parker; Helen Patterson; Martin Russell; Christopher Scrase; Chris South; John Staffurth; Emma Hall
Journal:  Lancet Oncol       Date:  2011-12-12       Impact factor: 41.316

2.  Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer.

Authors:  Sabbir Hossain; Ping Xia; Kim Huang; Martina Descovich; Cynthia Chuang; Alexander R Gottschalk; Mack Roach; Lijun Ma
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-03       Impact factor: 7.038

3.  Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

Authors:  Patrick A Kupelian; Louis Potters; Deepak Khuntia; Jay P Ciezki; Chandana A Reddy; Alwyn M Reuther; Thomas P Carlson; Eric A Klein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-01-01       Impact factor: 7.038

4.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.

Authors:  David P Dearnaley; Matthew R Sydes; John D Graham; Edwin G Aird; David Bottomley; Richard A Cowan; Robert A Huddart; Chakiath C Jose; John Hl Matthews; Jeremy Millar; A Rollo Moore; Rachel C Morgan; J Martin Russell; Christopher D Scrase; Richard J Stephens; Isabel Syndikus; Mahesh K B Parmar
Journal:  Lancet Oncol       Date:  2007-06       Impact factor: 41.316
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.